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studies with magnetic resonance 
spectroscopy.
Finally, a 600-MHz spectrometer is 
currently very expensive for routine 
use, whereas a much lower-field mag­
net, e.g. 400 MHz, could be used 
in front-line screening of untreated 
urine for inherited disorders. We 
agree that for further characteriza­
tion of certain specific disorders, es­
pecially where low concentrations of 
important metabolites are found, the 
superior sensitivity, resolution, and, 
for nonvolatile compounds, quantifi­
cation demonstrated by Wevers et al. 
is justified.
Nonetheless, 1H-NME analysis of 
unextracted urine offers a simple and 
rapid, noninvasive method for screen­
ing, diagnosis, and monitoring of met­
abolic disorders in children and in­
fants, including neonates. In such 
work, time of analysis and ease of 
interpretation of the result are often 
of the essence. Although even at 400 
MHz the technique is not yet inexpen­
sive and widely available, it appears 
to us illogical to promote the applica­
tion of even more expensive high-field 
instrumentation coupled with com­
plex sample preparation procedures 
and invasive patient sampling when 
field-proven and simpler alternatives 
already exist.
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The authors of the paper referred to 
reply:
To the Editor:
We have the following comments in 
response to the letter of lies et al.: 
Sample choice for diagnosing in­
born errors of metabolism. Most pa­
pers on NMR spectroscopy in body 
fluids of patients with inherited met­
abolic disease have used urine as a 
sample. In our experience, however, 
for many patients whose clinical signs 
and symptoms suggest an inborn er­
ror of metabolism, our laboratory is 
unable to make the diagnosis by us­
ing conventional techniques. Thus we 
decided to study urine, blood plasma, 
and CSF from this group of patients 
by NMR spectroscopy. Each of these 
body fluids contains some metabolites 
that do not occur in the other two 
fluids or occur only in a much lower
concentration. The many as-yet unas­
signed resonances that we have found 
both in blood plasma and in CSF 
illustrate that much is still to be 
learned (1,2). At 600 MHz, urine 
spectra may contain >350 resonances 
outside the glucose area (3.30-3.95 
ppm). Furthermore, the spectra of 
urine samples are complicated by 
baseline problems. Under the condi­
tions used in our studies (1, 2), CSF
pectra contain fewer res­
onances than urine spectra and can 
therefore be interpreted more easily. 
A metabolic disturbance relevant for 
the diagnosis may remain unnoticed 
in the spectrum of the patient’s urine 
but may be readily observed in the 
plasma or CSF spectrum. Such is not 
the case for organic acidurias, where 
the metabolites of interest generally 
occur in high concentrations in the 
urine. Our group, however, also aims 
to diagnose other known and as-yet 
unknown inborn errors of metabolism 
with 1H-NMR spectroscopy. Such dis­
eases may be characterized by abnor­
mal metabolite concentrations in the 
low micromolar range, and the rele­
vant resonances may be easily over­
looked among the many resonances 
present in a urine spectrum.
We think no general rule makes 
urine more suited than other body 
fluids for diagnosing an inborn error 
of metabolism with NMR spectros­
copy. Further studies will have to 
show whether or not NMR spectros­
copy of blood plasma and CSF can 
provide additional diagnostic infor­
mation that cannot be found in the 
urine of these patients.
About sample preparation. We agree 
that NMR spectroscopy can detect vari­
ous inborn errors of metabolism with 
intact urine samples. Blood plasma sam­
ples may also be analyzed without any 
sample pretreatment. Such studies often 
used the spin-echo technique, which has 
drawbacks for quantification of metabo­
lites. The study of Foxall et al. (3; see 
their Fig. la) shows poor spectral resolu­
tion even at 750 MHz. Spin-echo and 
two-dimensional J-resolved NMR spec­
tra are required to resolve and to re­
cognize the resonances. Quantification, 
however, remains problematic because of 
potential T2-differences between metab­
olite resonances and because of residual 
broad components (Fig. lb of Foxall et 
al.). We decided (a) to eliminate proteins 
and HaO to improve spectral quality 
(1,2) and (b) to use single-pulse NMR 
spectroscopy instead of spin-echo NMR 
spectroscopy. We are convinced that this 
was a decisive step forward because it 
allowed reliable quantification of almost 
every metabolite in the spectrum.
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Standardizing the pH of the sample 
can minimize intersample variation 
in the chemical shift of resonances 
(1, 2 ) and helped us in interpreting 
the plasma spectra. This step is even 
more beneficial for urine and CSF 
spectra because pH of these body flu­
ids has a greater intersample varia­
tion (1, 2). Minimizing intersample 
variation of the chemical shift of a 
resonance will be of great help for 
future automation of spectral analy­
sis (assignment and quantification of 
metabolites).
We agree with lies et al. that there 
seems to be no ideal pH that can avoid 
overlap of resonances. In our choice of 
pH we were lead by the arguments 
given in the earlier study by Lehnert 
and Hunkier (4) and by their already 
available database of relevant metab­
olites at this pH. lies et al. suggest 
measuring the sample first at its nat­
ural pH, followed by repeat analyses 
at acidic (2.5) and alkaline pH (8.5) if 
necessary. Analytically, there are no 
reasons to prefer the physiological pH 
of the sample. Given the complexity of 
the spectra and the inters ample vari­
ability in pH, it is not enough to 
record the pH of the sample. The 
natural pH of the sample simply has 
an unacceptable intersample varia­
tion (especially urine and CSF), 
which hampers the assignment of res­
onances. This may be why lies et al. 
require the presence of both the dou­
blet and the quartet resonances from 
methylmalonic acid for the diagnosis 
of methylmalonic aciduria from a 
urine sample. To be able to use the 
same model compound database for 
the interpretation of spectra from all 
body fluids, we decided to use a com­
mon pH (2.50) throughout our work 
(blood plasma, CSF, and urine). This 
seems more straightforward than 
working at three different pH values 
to avoid a simple two-step sample 
preparation (1. remove proteins by 
filtration, 2. control pH) before evap­
oration and reuptake in D20. We do 
not consider this “a complex sample 
preparation” that uses “a lengthy ex­
traction procedure” (1, 2).
The spectrometer. The increasing 
field strengths available in NMR 
spectroscopy open new possibilities 
that must be explored. At present, a 
600-MHz machine is still very expen­
sive, but prices may come down, just 
as they have for 400-MHz spectrome­
ters. Clearly, studies at 600 MHz give 
better-resolved spectra and a higher 
sensitivity than studies at 400 MHz, 
thus providing more information and 
allowing easier interpretation and 
(automated) quantification. Even if
one selects a lower field system (e.g., 
400 MHz) as a front-line screening 
machine for metabolic disease, the 
NMR findings obtained at 600 MHz 
will be extremely relevant.
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Positive Interference from 
Homocystinuria Urine in a Spot 
Test for Molybdenum Cofactor 
Deficiency
To the Editor:
Molybdenum cofactor deficiency 
and homocystinuria share certain 
clinical features. The former, an auto­
somal recessive disorder, results from 
combined deficiency of sulfite oxidase, 
xanthine dehydrogenase, and alde­
hyde oxidase (I ) and is characterized 
by severe neurological abnormalities, 
dislocated ocular lenses, mental re­
tardation, and excessive urinary ex­
cretion of sulfite, thiosulfate, <S-sulfo- 
cysteine, taurine, xanthine, and 
hypoxanthine. For simple diagnosis 
of molybdenum cofactor deficiency, 
urinary sulfite is easily detected in 
fresh urine specimens with a strip 
test (Merckoquant® 10013, E. Merck, 
Darmstadt, Germany; or Macherey- 
Nagel Quantofix® S03 , Gallard 
Schlesinger Industries, Carle Place, 
NY) (2). Homocystinuria, an inborn 
error of methionine metabolism most
commonly caused by a deficiency of 
cystathionine /3-synthase, is charac­
terized by accumulated homocysteine 
and methionine in plasma (3). Pa­
tients present clinically with dislo­
cated lenses, skeletal changes or os­
teoporosis, intravascular thrombosis, 
and sometimes mental retardation.
Duran et al. (4) reported a false- 
positive reaction for urinary sulfite 
after subjects were treated with the 
mucolytic drug 2-mercaptoethanesul- 
fonate. We report here a strong posi­
tive interference when the test was 
applied to the urine of a vitamin BQ- 
unresponsive homocystinuric patient 
on a regular diet.
The patient, a 9-year-old son of first 
cousins, had a history of some mental 
deficiency and speech problems. An 
ophthalmologic examination identi­
fied dislocated lens in the left eye and 
subluxed right lens. Physical exami­
nation noted a marfanoid stature 
with genu valgum. The diagnosis of 
homocystinuria was established at 
age 9 years after a plasma amino acid 
analysis by HPLC on two occasions 
yielded methionine concentrations of 
447 and 537 jamol/L (normal ^37
/xm oVL).
To evaluate the patient’s respon­
siveness to vitamin B6, we gave him a 
trial of 300-mg tablets of vitamin B6 
three times daily for ~40 days. At the 
end of this trial, his fresh urine was 
tested with a sulfite test strip 
(Merckoquant 10013), in an attempt 
to appreciate a possible enhancement 
of his deficient enzymatic activity 
(cystathionine /3-synthase) with sec­
ondary excretion of sulfite. This test- 
strip reaction was positive, although 
both parents and one brother gave 
negative reactions. His plasma methi­
onine content was still high (433 
/xmol/L), and the patient was consid­
ered vitamin B6-unresponsive. Sam­
ples of plasma, urine, and skin biopsy 
were sent to Jean-Marie Saudubray 
(Necker Hospital, Paris, France) for 
confirmation of the diagnosis of homo­
cystinuria. A later check of the pa­
tient’s urine while he was on a low- 
protein diet containing betaine 
citrate at 6 g daily gave a negative 
result for the sulfite test.
To identify the compound responsi­
ble for the positive sulfite test in this 
patient’s earlier urine, we investi­
gated several prepared solutions. 
Only compounds with free-SH radi­
cals, such as homocysteine, gave pos­
itive reactions (Table 1). In particular 
homocysteine gave a positive result at 
a concentration of 0.5 mmol/L; in com­
parison, a fivefold higher concentra­
tion of sodium sulfite was required.
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